SecBot SecBot
Biotech Drug Report Generated Nov 8, 2026

DARZALEX Faspro

HALO·HALOZYME THERAPEUTICS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available since 2020, with multiple FDA-approved indications. No additional regulatory milestones are pending for this specific product.
Why 4/10
DARZALEX Faspro is an approved, commercially mature product with no pending PDUFA or pivotal readout in the next 12 months from Halozyme's perspective. Halozyme is a technology licensor, not the drug developer, so the impact score is capped at 4; the stock's value drivers are quarterly royalty trends and pipeline updates rather than binary events for this drug.
Actionable Insight NEUTRAL

DARZALEX Faspro is an already-approved, commercially mature product with no upcoming binary catalyst for Halozyme. The next stock-moving events for Halozyme are quarterly royalty reports and the Merck Keytruda Qlex patent litigation outcome. Investors should watch J&J's quarterly daratumumab sales figures and Halozyme's Q4 2026 earnings for royalty growth trajectory.

Price Chart

Loading chart...

Executive Summary

DARZALEX Faspro (daratumumab and hyaluronidase-fihj) is a subcutaneous injectable formulation of Johnson & Johnson's blockbuster multiple myeloma drug, powered by Halozyme's ENHANZE drug-delivery technology. It generated $4.24 billion in global net sales in Q3 2026 alone. Halozyme earns royalties on DARZALEX Faspro sales as part of its ENHANZE licensing model, which produced a record $341 million in total royalty revenue for Halozyme in Q3 2026 (up 44% YoY). The drug recently expanded its label with FDA approvals for high-risk smoldering myeloma (Nov 2025), newly diagnosed transplant-ineligible myeloma quadruplet therapy (Jan 2026), and a TECVAYLI combo for relapsed/refractory myeloma (Mar 2026). However, DARZALEX Faspro is already a mature commercial product with no pending binary catalyst. Halozyme's stock recently dropped ~15.7% despite a Q3 beat and raised guidance, reflecting concerns about marginal upside and a Leerink downgrade.

How It Works

DARZALEX Faspro combines two components: daratumumab, a monoclonal antibody that targets CD38 proteins on multiple myeloma cells to flag them for destruction by the immune system, and Halozyme's ENHANZE technology (recombinant human hyaluronidase), an enzyme that temporarily breaks down hyaluronan under the skin to allow rapid absorption of larger injection volumes. This subcutaneous formulation replaces a time-consuming intravenous infusion (hours) with a quick under-the-skin injection (minutes).

Trial Status

DARZALEX Faspro is fully approved by the FDA for multiple myeloma and AL amyloidosis indications. Recent label expansions include high-risk smoldering myeloma (Nov 2025), newly diagnosed transplant-ineligible myeloma (Jan 2026), and combination with TECVAYLI for relapsed/refractory myeloma (Mar 2026). Additional clinical studies (e.g., TALVEY combination, Phase 3 MajesTEC-3) continue to explore expanded use.

The Two-Sided Case

▲ Bull Case5
DARZALEX Faspro generated $4.239 billion in global net sales in Q3 2026 alone, a massive and growing revenue stream that generates substantial ENHANZE royalties for Halozyme.
Halozyme's Q3 2026 ENHANZE royalty revenue jumped 44% YoY to a record $341 million, with DARZALEX Faspro being a major contributor.
Multiple recent FDA approvals (smoldering myeloma Nov 2025, NDMM quadruplet Jan 2026, TECVAYLI combo Mar 2026) continue to expand the addressable market.
Halozyme raised full-year 2026 guidance after Q3, projecting total revenue of $1.86B-$1.925B and non-GAAP EPS of $8.75-$9.05.
Analyst consensus remains bullish with 13 Buy/Strong Buy vs 3 Hold ratings and a mean price target of ~$109 (5% upside from the $103.63 close).
▼ Bear Case5
DARZALEX Faspro is a mature marketed product; no binary catalysts remain for Halozyme shareholders tied to this drug.
Halozyme's ENHANZE royalty stream depends on partner product sales, which could face pricing pressure or competition from oral/next-gen therapies.
The recent 15.7% stock drop (Nov 6) despite a Q3 beat reflects concerns about marginal guidance raise and a Leerink downgrade to Market Perform.
CEO Helen Torley executed substantial insider sales in October 2026 (pre-planned 10b5-1), which may worry some investors about valuation timing.
Medicare drug price negotiations could theoretically pressure DARZALEX sales long-term, though Halozyme projects minimal impact through at least 2035.

Upcoming Catalysts

  • Halozyme Q4 2026 earnings report (early Feb 2027) showing royalty growth trajectory
  • Merck Keytruda Qlex patent litigation developments (Dutch court injunction already won, other European markets pending)
  • New ENHANZE partnership announcements
  • Hypercon and Aerocon pipeline progress updates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

HALOZYME THERAPEUTICS, INC. 8-K HALO ·Originating report

Sources · 9

Hover a chip for the title
1 markets.businessinsider.com2 medscape.com3 streetinsider.com4 msn.com5 securities.io6 seekingalpha.com7 investors.com8 sec.gov9 webmd.com